1. Amicus Therapeutics will present at key investor conferences in September 2025. 2. Presentations scheduled for Sept 3 and Sept 9 in New York, NY. 3. Live webcasts available on the corporate investor's section of their website. 4. Company focuses on innovative medicines for rare diseases. 5. Emphasis on advancing best-in-class medicines for patient needs.
The upcoming presentations can attract investor interest and enhance visibility, potentially leading to positive market sentiment. Previous similar events have historically boosted stock prices for biotech firms.
The article's focus on investor engagement is crucial for FOLD's market perception and investment attractiveness. Healthy stock performance relates to effective communication with investors, suggesting an engaged investor base may lead to stock price support.
The investor conferences are imminent, presenting immediate opportunities for valuation changes based on market reactions. Companies often see significant price movement in the short term following investor updates.
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company's website at www.amicusrx.com, and follow on X and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Vice President, Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
